Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
It is developing the drug candidate to potentially treat immunological diseases
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
In clinical trials, treatment proved more effective than other therapies evaluated
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Subscribe To Our Newsletter & Stay Updated
